Fablyns sikkerhed ved osteoporosebehandling blev også vurderet i et fase- 2 placebokontrolleret studie med japanske, koreanske og taiwanesiske kvinder.
The safety of FABLYN in the treatment of osteoporosis was also assessed in a Phase 2 placebo-controlled trial in Japanese, Korean and Taiwanese women.